MedTrace Logo

Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients

NCT02995772 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2019-06-19

No results posted yet for this study

Summary

This study compared long term outcome of stage IIIB/C and IV breast cancer patients treated with neoadjuvant hormonal therapy (NAHT) and those treated with neoadjuvant chemotherapy (NACT)

Conditions

Interventions

DRUG

Aromatase Inhibitors (Arimidex)

Comparison of efficacy with chemotherapy

DRUG

Tamoxifen

Comparison of efficacy with chemotherapy

PROCEDURE

SOB

Comparison of efficacy with chemotherapy

DRUG

FAC

Comparison of efficacy with hormonal therapy

DRUG

Aromatase Inhibitors (Femara)

Comparison of efficacy with chemotherapy

DRUG

Aromatase Inhibitors (Aromasin)

Comparison of efficacy with chemotherapy

Sponsors & Collaborators

  • Dharmais National Cancer Center Hospital

    lead OTHER_GOV

Principal Investigators

  • Ramadhan Karsono, Doctoral · Dharmais National Cancer Center Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2018-11-30
Completion
2018-11-30

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02995772 on ClinicalTrials.gov